Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (61-70 of 202) with videos related to

Pageof 21
Sort By:
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 3, 2021
Endometrial Mesonephric-like Adenocarcinoma Presenting as an Ocular Lesion: A Case ReportSafia Al Nabhani, Aoife Doyle, Susan Kennedy, et al.
Breast Cancer Research and Treatment|July 13, 2007
Prevalence and prognostic and predictive relevance of PRAME in breast cancerPadraig Doolan, Martin Clynes, Susan Kennedy, et al.
Acta Oncologica (Stockholm, Sweden)|June 15, 2007
Bisphosphonate induced osteonecrosis of the jaws: unravelling uncertainty in disease causalityFergal C Kelleher, Malachi McKenna, Conor Collins, et al.
Translational Oncology|June 13, 2024
Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerSubhasree Rajaram, Naoise C Synnott, John Crown, et al.
Plos One|May 9, 2017
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer modelsTapesh Santra, Sandra Roche, Neil Conlon, et al.
BMJ Case Reports|February 5, 2021
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritisKieran Murray, Achilleas Floudas, Ciara Murray, et al.
BMC Cancer|June 1, 2012
Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic miceAgnieszka M Zagozdzon, Patrick O'Leary, John J Callanan, et al.
Molecular Cancer|October 1, 2024
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Investigational New Drugs|March 16, 2010
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cellsNorma O'Donovan, Annette T Byrne, Aisling E O'Connor, et al.
Molecular Cancer|January 31, 2025
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Pageof 21

Showing results (61-70 of 202) with videos related to

Sort By:
Pageof 21
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 3, 2021
Endometrial Mesonephric-like Adenocarcinoma Presenting as an Ocular Lesion: A Case ReportSafia Al Nabhani, Aoife Doyle, Susan Kennedy, et al.
Breast Cancer Research and Treatment|July 13, 2007
Prevalence and prognostic and predictive relevance of PRAME in breast cancerPadraig Doolan, Martin Clynes, Susan Kennedy, et al.
Acta Oncologica (Stockholm, Sweden)|June 15, 2007
Bisphosphonate induced osteonecrosis of the jaws: unravelling uncertainty in disease causalityFergal C Kelleher, Malachi McKenna, Conor Collins, et al.
Translational Oncology|June 13, 2024
Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerSubhasree Rajaram, Naoise C Synnott, John Crown, et al.
Plos One|May 9, 2017
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer modelsTapesh Santra, Sandra Roche, Neil Conlon, et al.
BMJ Case Reports|February 5, 2021
First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritisKieran Murray, Achilleas Floudas, Ciara Murray, et al.
BMC Cancer|June 1, 2012
Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic miceAgnieszka M Zagozdzon, Patrick O'Leary, John J Callanan, et al.
Molecular Cancer|October 1, 2024
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Investigational New Drugs|March 16, 2010
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cellsNorma O'Donovan, Annette T Byrne, Aisling E O'Connor, et al.
Molecular Cancer|January 31, 2025
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Pageof 21